Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus pemetrexed plus platin
nivolumab plus ipilimumab
CheckMate 227 (NI vs C ; PDL1>1%), 2018
  NCT02477826
RCTmNSCLC - L1 - PDL1 positivenivolumab plus ipilimumabplatinium chemotherapypatients with histologically confirmed squamous or nonsquamous stage IV or recurrent NSCLC who had received no previous systemic anticancer therapy and PDL1>1%396 / 397some concern
conclusif
  • demonstrated 21 % decrease in deaths (OS) (PE)
  • suggested 18 % decrease in progression or deaths (PFS)